GlassScriptPhysician profile
Sneha Patel
NPI 1902338833
$2,197.84
in general payments reported to CMS, 2019-2025
21 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $136 · 2024: $789 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Education: $17.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.21 |
| Education | $17.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.79 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $337.26 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.79 | 2024-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $177.54 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $174.59 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $132.72 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $93.97 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $91.00 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $88.13 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $62.50 | 2023 | Zeposia |
| Celgene Corporation | $60.51 | 2023-2024 | Zeposia, Camzyos |
| Qol Medical, LLC | $56.05 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $43.70 | 2025 | Rezdiffra |
| Celltrion USA INC. | $36.03 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $31.85 | 2025 | Omvoh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $25.10 | 2024 | Rebyota |
| Pfizer INC. | $23.26 | 2025 | |
| Biocon Biologics INC | $20.60 | 2025 | Yesintek |
| Ironwood Pharmaceuticals, INC | $18.54 | 2024 | |
| Capsovision, INC. | $18.15 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $17.76 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.